Title:Early Blockage of Mycobacterium Tuberculosis Cell-wall Synthesis via
EchA\6 Inhibition to Overcome Resistance Strain: Insights from Umbrella
Sampling Simulations
Volume: 19
Issue: 10
Author(s): Rafee Habib Askandar, Farhad Sharifi, Sepideh Shayan, Helya Mohammadi, Arian Rahimi, Noeman Ardalan*Heshw Farhad Mohammed
Affiliation:
- Department of Microbiology, Science and Research Branch, Islamic Azad University, Tehran, Iran
Keywords:
Tuberculosis, EchA6 inhibitor, molecular docking, molecular dynamics simulation, umbrella sampling, Mycobacterium tuberculosis.
Abstract:
Background: Tuberculosis (TB) has long been the major infectious cause of mortality,
ranking higher than HIV/AIDS as the most common cause of death from a single infectious agent
worldwide. The EchA6 target of mycobacteria plays a vital role in synthesizing an important component
of the mycobacterial outer membrane. The failure of TB treatment has prompted the investigation
of novel anti-tubercular drugs.
Objective: This study was aimed at blockage of Mycobacterium tuberculosis cell-wall synthesis via
EchA6 inhibition to overcome resistance strain.
Methods: Over 3,000,000 compounds and GSK951A (positive control) were investigated as the
inhibitors in this study. The GROMACS molecular dynamic package was used to analyze the protein-
inhibitor complex's conformational changes under constant temperature and pressure. Also,
umbrella sampling (US) was used for free binding energy (ΔG) calculation.
Results: Four compounds were chosen for the docking investigation. According to the MD analysis,
the studied inhibitors demonstrated good stability and flexibility. According to ΔG obtained from US,
the ΔG of GSK951A, ZINC11815220, ZINC67770050, ZINC55048326, and ZINC89700914 were
-6.14 kcal mol-1, -5.25 kcal mol-1, -10.19 kcal mol-1, -8.55 kcal mol-1, and -8.37 kcal mol-1, respectively.
Conclusion: In conclusion, ZINC67770050 is recommended for further study in the laboratory.
This investigation is an important starting point for discovering anti-tubercular drugs using EchA6
inhibition.<.p>